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Background: New-onset diabetes mellitus after a pancreaticoduodenectomy (PD) remains poorly
defined. The aim of this study was to define the incidence and predictive factors of immediate post-
resection diabetes mellitus (iPRDM).
Methods: Retrospective review of patients undergoing PD from January 2004 through to July 2010.
Immediate post-resection diabetes mellitus was defined as diabetes requiring pharmacological treatment
within 30 days post-operatively. Logistic regression was conducted to identify factors predictive of
iPRDM.
Results: Of 778 patients undergoing PD, 214 were excluded owing to pre-operative diabetes (n = 192),
declined research authorization (n = 14) or death prior to hospital discharge (n = 8); the remaining 564
patients comprised the study population. iPRDM occurred in 22 patients (4%) who were more likely to be
male, have pre-operative glucose intolerance, or an increased creatinine, body mass index (BMI),
pre-operative glucose, operative time, tumour size or specimen length compared with patients without
iPRDM (P < 0.05). On multivariate analysis, pre-operative impaired glucose intolerance (P < 0.001),
pre-operative glucose  126 (P < 0.001) and specimen length (P = 0.002) were independent predictors of
iPRDM. A predictive model using these three factors demonstrated a c-index of 0.842.
Discussion: New-onset, post-resection diabetes occurs in 4% of patients undergoing PD. Factors
predictive of iPRDM include pre-operative glucose intolerance, elevated pre-operative glucose and
increased specimen length. These data are important for patient education and predicting outcomes after
PD.
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Introduction
Post-resection diabetes mellitus (PRDM) is a poorly defined
sequela of major pancreatic resection (PR), with a reported inci-
dence ranging from 0% to 50%.1–9 Reasons for this wide range
include variable indications for resection, variable follow-up and
small sample size. Whereas substantial effort has been expended
to define major complications after a pancreaticoduodenectomy
(PD) such as pancreatic leak, delayed gastric emptying and
post-operative haemorrhage, relatively little has been done to
evaluate post-operative diabetes in terms of incidence and
predictive factors.
The aetiology of endocrine insufficiency in the post-resection
period is likely multifactorial. Contributing factors not only
include loss of pancreatic parenchyma and alteration of neuro-
hormonal responses after resection, but also include recurrence or
progression of underlying pancreatic disease, progressive gland
atrophy and adjuvant treatments such as chemotherapy or radia-
tion. The aim of this study was to evaluate the immediate effects of
PD (parenchymal loss and physiologic alterations) on the inci-
dence of post-resection diabetes. This determination is important
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in that the incidence of PRDM is a consideration in the surgeon’s
procedure-specific recommendation and the patient’s consent to
the operation.
Methods
The Mayo Clinic Institutional Review Board approved this study.
We performed a retrospective review of all consecutive patients
undergoing PD at our institution between January 2004 and July
2010. Data were collected from the medical records with regard to
patient demographics, indications for surgery, peri-operative data
and outcomes. Patients with a pre-operative diagnosis of diabetes
were excluded. Diabetes was defined as elevated serum glucose
requiring pharmacological treatment. Patients with a diagnosis of
impaired glucose tolerance, impaired fasting glucose or who had
elevated fasting blood glucose (FBG) levels but had no formal
diabetes evaluation or treatment pre-operatively were included.
Patients were followed for 30 days from surgery, recording com-
plications and outcomes including glucose levels and need for
pharmacological treatment for elevated glucose. Patients requir-
ing insulin or an oral hypoglycaemic agent within 30 days after
operating were considered to have immediate post-resection dia-
betes mellitus (iPRDM).
Univariate and multivariable associations with iPRDM were
evaluated using logistic regression models and summarized with
odds ratios (ORs) and 95% confidence intervals (CIs). A multi-
variable model was developed using a stepwise selection proce-
dure with the P-value as a feature to enter or leave the model set to
0.05. Statistical analyses were performed using the SAS software
package (SAS Institute, Cary, NC, USA). All tests were two-sided
and P-values < 0.05 were considered statistically significant.
Results
Of 778 consecutive patients undergoing PD performed at the
Mayo Clinic in Rochester,MN between 1 January 2004 and 31 July
2010, 214 patients were excluded from the analysis because of a
pre-operative diagnosis of diabetes (n = 192, 15 diabetes mellitus
type 1, 177 diabetes mellitus type 2), having declined Minnesota
Research Authorization (n = 14) or peri-operative mortality pre-
venting evaluation of diabetes (n = 8). The remaining 564 patients
represent the cohort for this study.
The mean age of this cohort was 64 years, with a mean body
mass index (BMI) (kg/m2) of 27, and 55% were male. Comorbidi-
ties included hypertension in 243(43%), obesity (BMI 30) in
113 (20%), and renal insufficiency (creatinine > 1.2) in 45 patients
(9%). A family history of DMwas reported in 191 patients (35%).
Amongst the 490 patients with available pre-operative glucose
levels, pre-operative fasting blood glucose (FBG) values were
found to be < 100 mg/dl in 191 patients (39%), between 100–
125 mg/dl in 242 (49%), and 126 mg/dl in 57 patients (12%).
Indications for surgery were malignancy in 421 (75%) and benign
in the remaining patients (Table 1). The most common diagnoses
included pancreatic adenocarcinoma (n = 241), an intraductal
pancreatic mucinous neoplasm (n = 66), ampullary adenocarci-
noma (n = 51) and a pancreatic neuroendocrine tumour (n = 36).
Only 31 patients (6%) in this series underwent PD for chronic
pancreatitis-related symptoms or complications. A pylorus-
preserving technique was performed in 455 patients (81%) with
the remainder receiving a standard PD. A totally laparoscopic
approach for PD was used in 78 patients (14%). The mean opera-
tive time and estimated blood loss was 361 min and 646 ml,
respectively. A peri-operative blood transfusion was given in 223
patients (40%). On histopathology review, the mean tumour size
and specimen length were 3.3 cm and 6.7 cm, respectively.
In the immediate (30 days) post-operative period, 226 patients
(40%) had normal FBG levels and required no hyperglycemia
treatment. In 316 patients (56%), transiently elevated glucose
levels required peri-operative insulin treatment; however, treat-
ment was discontinued during hospitalization because of normal-
ization of FBG levels without treatment. Persistently elevated FBG
levels occurred in 22 patients (4%) requiring ongoing treatment
with insulin (n = 20) or an oral hypoglycemic agent (n = 2) and
were therefore considered to have iPRDM. When evaluating
patients with normal pre-operative glucose levels (<100 mg/dl),
impaired fasting glucose (100–125 mg/dl) and those with
impaired glucose tolerance or FBG 126 mg/dl, the incidence of
iPRDM increased from 1%, 3% and 19%, respectively (Fig. 1).
Univariate analysis was performed to identify factors associated
with iPRDM (Table 2). Factors with a significant association with
iPRDM included male gender (OR 3.88, P = 0.015), pre-operative
impaired glucose tolerance (OR 26.11, P < 0.001), pre-operative
glucose 126 mg/dl (OR 20.11, P < 0.001), BMI (5 unit increase,
OR 2.0, P < 0.001), pre-operative creatinine (1 unit increase, OR
3.83, P = 0.019), operative time (100 min. increase, OR 1.80,
P = 0.013), tumour size (1 cm increase OR, 1.16, P = 0.019) and
specimen length (1 cm increase OR, 1.4, P = 0.005). A family
Table 1 Indications for operation in patients undergoing a
pancreaticoduodenectomy
Diagnosis Frequency Per cent
Malignant
Pancreatic ductal adenocarcinoma 241 42.7
Ampullary adenocarcinoma 51 9.04
Duodenal adenocarcinoma 29 5.14
Periampullary adenocarcinoma 24 4.26
Cholangiocarcinoma 24 4.26
Neuroendocrine tumour (malignant) 23 4.08
Other (malignant) 29 5.14
Benign
Intraductal papillary mucinous neoplasm 66 11.7
Chronic pancreatitis 31 5.5
Neuroendocrine tumour (benign) 13 2.3
Cystadenoma 9 1.59
Other (benign) 24 4.26
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history of DM, age, hypertension, indication for surgery, malig-
nancy, laparoscopic approach and pylorus-preserving technique
all showed no significant associations with PRDM.
Upon multivariable analysis, only preoperative impaired
glucose tolerance (OR 15.5, P < 0.001), pre-operative glucose 
126 (OR 6.43, P < 0.001) and specimen length (OR 1.53, P =
0.002) were independent predictors of iPRDM (Table 3). A pre-
dictive model using these three factors demonstrated a c-index of
0.842.
Discussion
When counselling patients for a PR, the question is often raised
about the risk of developing diabetes post-operatively. The
reported incidence of post-resection diabetes mellitus after PD
varies in the literature from 0% to 50% and comes from series
with various patient populations, small sample size and variable
follow-up.1–9 The answer is even more complex acknowledging
that the resection itself represents only a portion of the risk, as
underlying disease progression, gland atrophy, weight loss or gain,
diet and adjuvant chemotherapy or radiation may also contribute
to the development of PRDM.
We report a large, single-institutional series of patients under-
going PD where the overall incidence of iPRDMwas 4%. This is at
the lower end of that reported in most previous studies and is
likely accounted for by several factors including a low incidence of
patients with chronic pancreatitis, larger sample size and the
short-term (30 day) follow-up design of this study.We intention-
ally limited the evaluation to the first 30 days post-operatively to
avoid confounding factors exclusive of resection. This provided
the opportunity to attempt to define the independent effect of the
loss of pancreatic parenchyma and physiological changes that
occur as a result of the pancreatic resection.
The current literature suggests that patients undergoing PD
continue to be at risk for diabetes mellitus in themonths and years
after the operation, whereas conflicting series show no significant
changes over time.7,8 Seiler and colleagues reported a 6.4% inci-
dence of iPRDM after PD at 12 months follow-up.9 In a previous
study utilizing oral glucose tolerance testing (OGTT) pre-
operatively, 3 months post-operatively, and yearly thereafter, Ish-
ikawa and colleagues demonstrated that patients with a normal
Figure 1 Incidence of immediate post-resection diabetes mellitus
after a pancreaticoduodenectomy amongst 490 patients with avail-
able pre-operative glucose levels. Overall incidence is 4%. Incidence
is low if FBG is normal and increases with abnormal FBG or diagnosis
of IGT. FBG, fasting blood glucose; IGT, impaired glucose tolerance
Table 2 Univariate analysis of potential risk factors for immediate
post-resection diabetes mellitus (iPRDM) in patients undergoing a
pancreaticoduodenectomy
Variable Odds ratio (95% CI) P-value
Year of operation (1-year
increase)
0.79 (0.62–1.00) 0.046
Age at operation (10-year
increase)
1.27 (0.88–1.83) 0.21
Male 3.88 (1.30–11.62) 0.015
Pre-operative FBG (20-unit
increase)
1.91 (1.47–2.47) <0.001
Preoperative FBG
<100 mg/dl 1.0 (reference)
100–125 mg/dl 3.65 (0.78–17.10) 0.1
126 mg/dl 20.11 (4.26–94.87) <0.001
Impaired glucose tolerance 26.11 (9.59–71.15) <0.001
Family history of DM 0.87 (0.33–2.32) 0.78
Hypertension 1.61 (0.68–3.79) 0.28
BMI (5-unit increase) 2.00 (1.34–2.99) <0.001
BMI 30 2.38 (0.97–5.82) 0.06
Pre-operative creatinine (1-unit
increase)
3.83 (1.25–11.76) 0.019
Pre-operative creatinine > 1.2 2.67 (0.86–8.32) 0.09
Laparoscopic approach 0.61 (0.14–2.68) 0.52
Pylorus preserving 0.81 (0.29–2.24) 0.68
Operative time (100-minute
increase)
1.80 (1.13–2.85) 0.013
Estimated blood loss (500-cc
increase)
1.21 (0.95–1.54) 0.12
Transfusion 1.29 (0.55–3.03) 0.56
Malignant disease 0.72 (0.29–1.80) 0.48
Tumour size (1-cm increase) 1.16 (1.03–1.32) 0.019
Specimen length (1-cm
increase)
1.40 (1.11–1.78) 0.005
FBG, fasting blood glucose; DM, diabetes mellitus; BMI, body mass
index (kg/m2).
Table 3 Results of multivariable analysis of factors predictive
of immediate post-resection diabetes mellitus (iPRDM) after a
pancreaticoduodenectomy
Variable Odds ratio (95% CI) P-value
Impaired glucose tolerance 15.50 (5.04–47.66) <0.001
Pre-operative FBG
125 mg/dl 1.0 (reference)
126 mg/dl 6.43 (2.19–18.85) <0.001
Specimen length (1-cm increase) 1.53 (1.17–2.01) 0.002
FBG, fasting blood glucose.
172 HPB
HPB 2013, 15, 170–174 Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
preoperative OGTT showed no decline over time, whereas those
with abnormal OGTT patterns were likely to demonstrate a
decline in glucose tolerance.8 These differences may be attributed
to the multiple confounding factors independent of PR alone.
Long-term procedure-related factors such as stricturing of the
pancreatic anastomosis and delayed effects of altered neurohor-
monal responses may also play a role. In a randomized, controlled
trial comparing pancreaticojejunostomy versus pancreatic duct
ligation, a two-fold incidence of PRDM was observed in patients
with duct ligation.10
In the present study, the incidence of iPRDM was not differ-
ent for patients with malignant indications for resection com-
pared with those with benign indications. Resection for
pancreatic adenocarcinoma may actually have a beneficial effect
on ameliorating diabetes or reducing its likelihood, as a modest
causal association has been demonstrated between pancreatic
cancer and type II diabetes.11 In patients with new-onset diabetes
and pancreatic adenocarcinoma, PR has been shown to amelio-
rate diabetes in more than 50% of patients, suggesting a diabe-
togenic influence of cancer.12 However, for patients with a
diagnosis of chronic pancreatitis, the incidence of PRDM may
reflect the underlying disease progression in addition to the
effects of resection.2,4
We identified three factors predictive of iPRDM: impaired
glucose tolerance, FBG 126 mg/dl and increasing specimen
length. In this three-factor model, a favourable predictive ability
was observed with a c-index of 0.842. The first two of these factors
suggest that impaired glucose control increases the risk for diabe-
tes after PR. This has been demonstrated in several smaller
series.7,8 It is plausible that in this ‘pre-diabetic’ state, further loss
of insulin, glucagon and the altered neurohormonal response to
glucose induced by resection would increase the risk of progress-
ing to diabetes mellitus.13–15 Alternatively, these diagnoses also
suggest the possibility that some patients in this and other series
my actually have diabetes mellitus but are lacking a formal evalu-
ation and diagnosis. We acknowledge this as a limitation in this
study as we were unable to identify clear documentation that these
patients had a formal diabetes evaluation; this is in part reflective
of our tertiary practice where patients’ primary care evaluations
may have been done elsewhere.
According to the most recent publication of American Diabe-
tes Association (ADA), a FBG of 126 mg/dl is an independent
criteria for the diagnosis of DM.16 In the present study, if a
patient had a new finding of elevated FBG yet no other evalua-
tion or clinical documentation of DM, we elected to include
them in this study. The rationale for this is that the ADA criteria
have largely been established in asymptomatic patients without
pancreatic disease requiring operation, whereas many of the
patients in our cohort had possible confounding factors such as
obstructing pancreatic lesions, recent endoscopic procedures,
biliary stenting or cholangitis at the time of the FBG measure-
ment. Furthermore, justification of including these patients in
this study is that a minority of these patients had persistently
elevated FBG post-operatively. It is also noteworthy that this
group was less likely to develop iPRDM than those with
impaired glucose tolerance (OR 6.4 vs. 48.8). When grouped
together, the incidence of iPRDM for a patient with either con-
dition was 19%.
With the possibility of including patients with undiagnosed
DM in this study, one would expect the observed incidence of
iPRDM of 4% to be an overestimate of the true risk of iPRDM
after PD. Perhaps the most important and useful finding in this
study is that for patients with a normal pre-operative FBG, the
incidence of iPRDM is only 1%.
As of 2010, the ADA has included an HbgA1c of 6.5% as an
independent criterion for establishing the diagnosis of DM.17
During the time period of this study, HbgA1c was not a standard
part of the pre-operative evaluation of patients with elevated FBG
and therefore could not be evaluated as a predictor of iPRDM. It
has been shown that an elevated HgbA1C is predictive of PRDM
with a positive predictive value, negative predictive value, sensi-
tivity and specificity of 82%, 94%, 90% and 88%, respectively.18
Importantly, these authors reported the incidence of PRDM to be
very low if the HgbA1c is normal pre-operatively.
Increasing specimen length was also identified as a predictor of
iPRDM in our patient cohort. We did not evaluate remnant pan-
creatic volume in this study, but it is intuitive that patients with
a proportionally large pancreatic head or that required transec-
tion into the pancreatic body would be at an increased risk for
PRDM.
We identified several other factors associated with iPRDM on
univariate analysis such as elevated BMI and creatinine levels that
are known risk factors for the development of DM in the general
population, yet these failed to demonstrate any independent pre-
dictive ability for iPRDM. However, the low incidence of iPRDM
in this study limits the ability to perform a more complex statis-
tical evaluation and modelling of predictive factors.
In summary, iPRDM occurs in 4% of all patients undergoing
PD. Factors predictive of iPRDM include impaired glucose toler-
ance, elevated glucose and increasing specimen length. The last
two factors are easily determined pre-operatively and represent
patients at risk for progression to DM as well as patients with
potentially undiagnosed new-onset DM. The incidence of iPRDM
in patients with normal pre-operative FBG levels is only 1%; this
information is helpful for surgeons and their patients when con-
sidering PD as a treatment option for pancreatic disease. Further
studies to address the multifactorial aetiology of delayed onset
DM after PR are needed.
Conflicts of interest
None declared.
References
1. Lemaire E, O'Toole D, Suvanet A, Hammel P, Belghiti J, Ruszniewski P.
(2000) Functional and morphological changes in the pancreatic remnant
HPB 173
HPB 2013, 15, 170–174 Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
following pancreaticoduodenectomy with pancreaticogastric anastomo-
sis. Br J Surg 87:434–438.
2. Riediger H, Adam U, Fischer E, Keck T, Pfefer F, Hopt UT et al. (2007)
Long-term outcome after resection for chronic Pancreatitis in 224
Patients. J Gastrointest Surg 11:949–960.
3. Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P.
(2008) Pancreatic insufficiency after different resections for benign
tumours. Br J Surg 95:85–91.
4. Jimenez RE, Fernandez-del Castillo C, Rattner DW, Change Y, Warshaw
AL. (2000) Outcome of pancreaticoduodenectomy with pylorus preser-
vation or with antrectomy in the treatment of chronic pancreatitis. Ann
Surg 231:293–300.
5. Stone WM, Sarr MD, Nagorney DM, McIlrath DC. (1988) Chronic pancre-
atitis. Results of Whipple's resection and total pancreatectomy. Arch
Surg 123:815–819.
6. Sohn T, Campbell K, Pitt H, Sauter PK, Coleman J, Lillemoe KD et al.
(2000) Quality of life and long-term survival after surgery for chronic
pancreatitis. J Gastrointest Surg 4:355–365.
7. Litwin J, Dobrowolski S, Orlowska-Kunikowska E, Sledzinski Z. (2008)
Changes in glucose metabolism after kausch-whipple pancreatectomy
in pancreatic cancer and chronic pancreatitis patients. Pancreas 36:
26–30.
8. Ishikawa O, Ohigashi H, Eguchi H, Yokoyama S, Yamada T,
Takachi K et al. (2004) Long-term follow-up of glucose tolerance
function after pancreaticoduodenectomy: comparison between pancre-
aticogastrostomy and pancreaticojejunostomy. Surgery 136:617–
623.
9. Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W et al.
(2005) Randomized clinical trial of pylorus-preserving duodenopancre-
atectomy versus classical Whipple resection – long term results. Br J
Surg 92:547–556.
10. Tran K, Van Eijck C, Di Carlo V, Hop WC, Zerbi A, Balzano G et al. (2002)
Occlusion of the pancreatic duct versus pancreaticojejunostomy: a pro-
spective randomized trial. Ann Surg 236:422–428.
11. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F,
Woodward M. (2005) Type-II diabetes and pancreatic cancer: a meta-
analysis of 36 studies. Br J Cancer 92:2076–2083.
12. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST.
(2008) Prevelance and clinical profile of pancreatic cancer-associated
diabetes mellitus. Gastroenterology 134:981–987.
13. Schrader H, Menge BA, Breuer TG, Ritter PR, Uhl W, Schmidt WE et al.
(2009) Impaired glucose-induced glucagon suppression after partial pan-
createctomy. J Clin Endocrinol Metab 94:2857–2863.
14. Menge BA, Schrader H, Breuer TGK, Dabrowski Y, Uhl W, Schmidt W
et al. (2009) Metabolic consequences of a 50% partial pancreatectomy in
humans. Diabetologia 52:306–307.
15. Slezac A, Andersen DK. (2001) Pancreatic resection: effects on glucose
metabolism. World J Surg 25:452–460.
16. American Diabetes Association. (2012) Standards of medical care in
diabetes – 2012 position statement. Diabetes Care 25 (Suppl. 1):S11–63.
17. American Diabetes Association. (2012) Diagnosis and classification of
diabetes mellitus. Diabetes Care 34 (Suppl. 1):S64–71.
18. Hamilton L, Jeyarajah DR. (2007) HbA1c can be helpful in predicting
progression to diabetes after Whipple procedure. HPB 9:26–28.
174 HPB
HPB 2013, 15, 170–174 Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
